Moreover, studies involving drug-metabolizing enzyme activity have investigated enzymes like CYP3A4/5 (Diczfalusy et al., 2011), CYP3A4 (Rahmioglu et al., 2011), CYP3A (Shin et al., 2013), and CYP2D6 (Tay-Sontheimer et al., 2014) and diseases, including colorectal cancer (Backshall et al., 2011), depression (Kaddurah-Daouk et al., 2011b), lymphoid malignances (Muhrez et al., 2017), and so on. This evidence concerns the gene CYP3A4 and depressive symptom measurement.